A Pharmacokinetic Bridging Study to Compare Systemic Exposure to Budesonide between Budesonide Oral Suspension and ENTOCORT EC in Healthy Individuals

BACKGROUND AND OBJECTIVES: Currently, there are no US FDA-approved therapies for eosinophilic esophagitis (EoE). Budesonide oral suspension (BOS; SHP621, TAK-721) is a viscous, muco-adherent, oral formulation of budesonide that is in phase III development for the treatment of EoE. BOS 2 mg twice dai...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Ivy H., Finkelman, Richard D., Lan, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691405/
https://www.ncbi.nlm.nih.gov/pubmed/33057953
http://dx.doi.org/10.1007/s40268-020-00324-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691405/
https://www.ncbi.nlm.nih.gov/pubmed/33057953
http://dx.doi.org/10.1007/s40268-020-00324-1

Ejemplares similares